Newleos Therapeutics

We are thrilled to welcome Dr. Steve Brannan , a prominent leader in neuroscience and neuropsychiatric drug development and former Chief Medical Officer at Karuna Therapeutics, to our Board of Directors. Steve brings deep clinical expertise and a legacy of transformative CNS drug development. We are also proud to share that our lead candidate NTX-1955, a first-in-class GABAA-γ1 positive allosteric modulator, will enter Phase 1b clinical studies in generalized anxiety disorder in the EU. Dosing has already commenced for one of the studies which are an important step toward validating this novel mechanism in humans and advancing a new class of anxiolytics. With Steve’s insight and our growing clinical momentum, we are advancing a new generation of neuropsychiatric treatments that prioritize both efficacy and tolerability for patients. 👉 Read the announcement: https://xmrrwallet.com/cmx.pbit.ly/4i3wdkY #TeamNewleos #Neuroscience #MentalHealth #Biotech #ClinicalTrials #AnxietyDisorders #CNS #Leadership

We recently wrapped up a highly productive offsite facilitated by Kari Watson of Owl’s Head Strategies. It was a fantastic opportunity for our team to align on our corporate messaging and refine our communication strategy. A highlight of the offsite was a dynamic values workshop, where we defined the core principles that truly reflect the heart of Newleos' culture. Of course, we made time to unwind and bond—with a friendly (and competitive!) round of bowling. 🎳 Here’s to the future of Newleos—powered by shared values, clear vision, and a strong sense of teamwork! 🚀 #TeamNewleos #StrategicOffsite #CorporateCulture #BowlingFun

We're #hiring a new (Senior) Director, Clinical Pharmacology in Boston, Massachusetts. Apply today or share this post with your network.

We're #hiring a new Director, Clinical Sciences in Boston, Massachusetts. Apply today or share this post with your network.

We're #hiring a new Director, Clinical Sciences in Boston, Massachusetts. Apply today or share this post with your network.

This week, the #Newleos Therapeutics team is recognizing Anxiety Awareness Week. According to the WHO, over 300 million people suffer from anxiety. In the US, NIH estimates almost 50 million adults have suffered from an anxiety disorder in the last year and over 30% of adolescents aged 13-18 will experience an anxiety disorder. While therapeutic options to manage anxiety do exist, they are limited in terms of their efficacy and tolerability.   We are proud to be advancing a clinical pipeline that includes first- and best-in-class drugs designed to be highly efficacious while minimizing side effects typically associated with anti-anxiety medications. Our goal is to improve the lives of patients and usher in a new dawn - "eos" - in the treatment of mental health conditions. For more information on NTX-1955, being investigated for generalized anxiety disorder, or NTX-1472, being investigated in social anxiety disorder, please visit our website https://xmrrwallet.com/cmx.plnkd.in/e-ehTYuP

We are proud to welcome the inaugural members of our Clinical Advisory Board who will support the development of our neuropsychiatric product pipeline, including NTX-1955 for generalized anxiety disorder and NTX-1472 for social anxiety disorder. Featuring internationally recognized leaders in psychiatry and neuroscience with deep experience designing and executing pivotal trials in complex patient populations, these leaders share Newleos’ goal of addressing the increasing global burden of mental health conditions. We are honored to have such a distinguished group of experts supporting our work. Members include: Dr. Maurizio Fava (MGB/Harvard) Dr. Juliane Hellhammer, PhD (daacro) Dr. Michael Liebowitz (The Medical Research Network) Dr. Sanjay J. Mathew (Baylor) Dr. Gerard Sanacora (Yale) Dr. Murray Stein (UCSD) Read the full announcement: https://xmrrwallet.com/cmx.pbit.ly/4i3wdkY #MentalHealth #Neuroscience #ClinicalResearch #AnxietyDisorders #CNS #Biotech

We are delighted to welcome an accomplished group of professionals to the Newleos leadership team.   New clinical and medical leadership team members: Sondra Neale Smyrnios, Senior Vice President, Clinical and Technical Operations Adam Simmons, Vice President, Clinical Development and Operations Chris Jepsen, Vice President of Quality Tiffany Lago, MD, Executive Medical Director New corporate leadership team members: Lea Hachigian, Ph.D., Vice President, Corporate Strategy and Operations Kyle Audi, Vice President, Finance Brian Shea, Vice President, Head of Legal The collective experience and leadership of our expanded team enhances our operational capabilities and supports the advancement of our clinical-stage neuropsychiatric programs in anxiety, substance use disorders and cognitive impairment.   View today's press release at https://xmrrwallet.com/cmx.plnkd.in/ecMi8hii #TeamNewleos #Biotech #BiotechStartup #Neuropsychiatry #NewHires #Welcome #TeamGrowth

We're #hiring a new Director, Translational Science in Boston, Massachusetts. Apply today or share this post with your network.

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024. #pharma #Neuropsychiatric #biospace https://xmrrwallet.com/cmx.phubs.li/Q036zPn20